Morning session of China’s 2026 on-site national reimbursement price
negotiations and commercial-insurer innovative-drug catalog talks opened.
Company delegations queued outside and began entering; early entrants included
Kangyuan Pharmaceutical, Kangpu Pharmaceutical, China Resources Sanjiu, Qidu
Pharmaceutical, Zai Lab, North China Pharmaceutical, Yunding Xinyao, Qilu
Pharmaceutical, Kangzhe Pharmaceutical and Joincare. Several heavyweight
traditional Chinese medicine items cleared preliminary review and are now up for
negotiation, notably Guangyuyuan’s Banxia Xiexin Tang granules, Tasly’s Zaoren
Ningxin Diwan and Kangyuan’s Canpu granules.